USA flag logo/image

An Official Website of the United States Government

Oral Transmucosal Drug Delivery System for Nicotine

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
89025
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
DA025351
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BIONEX PHARMACEUTICALS, LLC
7 LAVENDER WAY EAST BRUNSWICK, NJ -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Oral Transmucosal Drug Delivery System for Nicotine
Agency: HHS
Contract: 1R43DA025351-01
Award Amount: $117,968.00
 

Abstract:

DESCRIPTION (provided by applicant): RESEARCH PROPOSED: Research is proposed to investigate the feasibility of design and fabrication of an oral transmucosal drug delivery system for systemic delivery of nicotine. The drug delivery system is intended to at tain a dual drug-release profile so that dual pharmacological actions, i.e., an initial rapid onset of action followed by period of prolonged effect, can be achieved. PROBLEM/OPPORTUNITY: Many drug-abuse medications (e.g., nicotine) cannot be effectively a dministered orally. Alternate drug delivery systems are therefore needed for drug abuse studies and in treatment clinics. The dosage form should also be convenient for administration, cost-effective, and provide controlled pharmacological actions. We propo se an oral transmucosal system that provides a rapid onset of drug action (to address period of acute craving) followed by a prolonged release of the drug to maintain a lower, constant drug plasma concentration. Such dual drug-release delivery system addre sses the therapeutic gap problems of the fast-onset dosage forms (e.g., injections and nasal sprays) and sustained-release delivery systems such as transdermal patches and depot implants. Also, this simple single-dosage form offers convenience of dose admi nistration (thus ensures compliance); is less expensive (vs. implants, transdermal, nasal and inhalation devices); and improves bioavailability of drugs with high first-pass metabolism or significant gastrointestinal degradation (vs. oral dosage forms). LO NG-TERM GOAL: The long-term goal of the proposed research is to develop a convenient, cost- effective, and controlled multiple drug-action thin-film transmucosal delivery system for drugs that can be effectively administered through the oral mucosa. This i nnovation provides an alternate dosage form to deliver medications, with controlled therapeutic dosage and action, which otherwise may not be efficaciously administered using conventional dosage forms. PLAN OUTLINE: Phase I task objectives are a) design an d fabrication of biphasic constructs with dual drug release (fast and slow) characteristics, to meet targeted fast onset of action and prolonged pharmacological effect of nicotine, b) development of in vitro drug release test method and testing of candidat e formulations, and c) development of in vitro transmucosal permeation evaluation method using cultured buccal epithelium and testing of candidate formulations to determine the bio-absorption efficiency of the formulations. Plans for follow-on Phase II res earch include completing product development program, and demonstration of efficacy in animals and preliminary human studies. COMMERCIAL OPPORTUNITY: The proposed drug delivery system can be used in research clinics to study potential improvement in effica cy of existing mediations or research experimental therapeutic agents. Furthermore, applications of this technology can be extended to commercial pharmaceutical market as a more efficacious form of administering drug-abuse medications (e.g., smoking cessat ion therapy). Public Health Relevance: The proposed study Oral transmucosal drug delivery system for nicotine aims at developing a novel and improved dosage form for smoking cessation therapy. The results may lead to greater cessation rates, and t hus bring improved health to cigarette smokers. Also, the proposed technology could be extended and developed into improved dosage forms of drug-addiction treatment medications.

Principal Investigator:

Business Contact:

Small Business Information at Submission:

BIONEX PHARMACEUTICALS, LLC
BIONEX PHARMACEUTICALS, LLC 7 LAVENDER WAY EAST BRUNSWICK, NJ 08816

EIN/Tax ID: 126034306
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No